Michael has made over 82 trades of the Durect Corp stock since 2006, according to the Form 4 filled with the SEC. Most recently Michael exercised 1,159 units of DRRX stock worth $1,820 on 13 June 2019.
The largest trade Michael's ever made was exercising 60,000 units of Durect Corp stock on 21 December 2015 worth over $6,650,400. On average, Michael trades about 7,284 units every 32 days since 2003. As of 3 June 2019 Michael still owns at least 24,666 units of Durect Corp stock.
You can see the complete history of Michael Casey stock trades at the bottom of the page.
Michael's mailing address filed with the SEC is C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT, NJ, 07901.
Over the last 21 years, insiders at Durect Corp have traded over $528,010 worth of Durect Corp stock and bought 19,954,650 units worth $23,296,708 . The most active insiders traders include April Fund Ltd21 April Fund..., Eagle Investment Management... oraz Felix Theeuwes. On average, Durect Corp executives and independent directors trade stock every 55 days with the average trade being worth of $468,485. The most recent stock trade was executed by Judith J. Robertson on 18 August 2022, trading 80,942 units of DRRX stock currently worth $68,801.
durect is a specialty pharmaceuticals company with expertise in drug discovery, drug delivery and drug development, applying those skills primarily to therapeutics in the fields of pain management, acute organ injury and metabolic diseases. durect’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as improved abuse deterrence, convenience, adherence, efficacy and safety for small molecule and biologic drugs. late stage development programs of this nature include remoxy® and posidur™. durect’s epigenomic regulator program includes the lead molecule dur-928 in phase 1 clinical testing. dur-928 is an endogenous small molecule that is an epigenomic modulator of cellular activities involved in lipid homeostasis, metabolic disease, inflammation and cell survival. for more information, please visit www.durect.com. we also manufacture and sell two commercial product lines: • alzet® osmotic pumps use
Durect Corp executives and other stock owners filed with the SEC include: